IE 11 is a very old browser and is not supported on this site.

Half year report 2021

The Galenica Group experienced strong growth in the first half of 2021. This was due in particular to one-off additional sales in connection with COVID-19, Verfora’s portfolio expansion, a pleasing increase in sales of the specialty pharmacy Mediservice and further market share gains in the physicians segment.


The Galenica Group made a major contribution toward the provision of healthcare to the people of Switzerland, in part through its products and services related to COVID-19.

To the foreword
Key figures

The Galenica Group generated consolidated net sales of CHF 1,857.1 million in the first half of 2021, corresponding to growth of 9.9% compared to the first half of 2020.


Net sales

in CHF million


EBIT adjusted1

in CHF million


Number of employees

at 30 June 2021

Products & Care

Development and marketing of healthcare services and products

The “Products & Care” segment comprises the “Retail” business area with offerings for patients and end customers (B2C) and the “Professionals” business area with offerings for business customers and partners in the healthcare sector (B2B).

Read more

Logistics & IT

Optimisation and further development of logistics offer and services

The “Logistics & IT” segment comprises the two sectors “Wholesale” and “Logistics & IT Services”. These provide services for all those involved in the healthcare sector – pharmacies, drugstores, doctors, hospitals and care homes, partners and suppliers.

Read more
Galenica uses cookies to optimise the functions of the website and to ensure you enjoy the best possible experience. Use of cookies & disclaimer